|Over a week ago|
Lundbeck upgraded to Neutral from Sell at Goldman Sachs » 17:2409/1509/15/20
Goldman Sachs analyst…
Goldman Sachs analyst Diana Na upgraded Lundbeck to Neutral from Sell with a DKK 214 price target. The analyst cited the stock's underperformance due to consensus earnings downgrades, along with multiple pipeline failures year-to-date. Na now sees a more balanced risk/reward following the share price decline.
|Over a month ago|
Lundbeck downgraded to Add from Buy at AlphaValue » 05:0608/2108/21/20
AlphaValue downgraded Lundbeck to Add from Buy.
Lundbeck price target raised to DKK 340 from DKK 334 at UBS » 14:2508/1708/17/20
UBS analyst Michael…
UBS analyst Michael Leuchten raised the firm's price target on Lundbeck to DKK 340 from DKK 334 and keeps a Buy rating on the shares.
Lundbeck price target lowered to DKK 218 from DKK 230 at Credit Suisse » 12:2508/1408/14/20
Credit Suisse analyst…
Credit Suisse analyst Trung Huynh lowered the firm's price target on Lundbeck to DKK 218 from DKK 230 and keeps an Underperform rating on the shares.
Lundbeck price target lowered to DKK 285 from DKK 295 at Barclays » 10:4608/1408/14/20
Barclays analyst Emily…
Barclays analyst Emily Field lowered the firm's price target on Lundbeck to DKK 285 from DKK 295 and keeps an Overweight rating on the shares.
Lundbeck stops Phase II schizophrenia study, says unlikely to hit endpoint » 09:5708/0508/05/20
H. Lundbeck announces the…
H. Lundbeck announces the decision to discontinue the Phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms. The decision to stop the trial is based on the results of a futility interim analysis, which concluded that the trial is unlikely to achieve statistical significance on its primary endpoint, mean change from baseline to week 12 on the Brief Negative Symptom Scale. The recommendation to stop the trial is not based on safety concerns, the company added.
|Over a quarter ago|
Lundbeck upgraded to Neutral from Underweight at JPMorgan » 07:5803/0403/04/20
JPMorgan analyst James…
JPMorgan analyst James Gordon upgraded Lundbeck to Neutral from Underweight with an unchanged price target of DKK 265. The analyst says his previous bearish view on the company's 2020 guidance now played out. Further, Lundbeck is set to offer mid-teens medium-term annual earnings growth, even with a cautious view on the Viepti migraine ramp, Gordon tells investors in a research note. He views the 2020 outlook as conservative and the stock's valuation "compelling."
Lundbeck upgraded to Neutral from Underweight at JPMorgan » 04:5603/0403/04/20
JPMorgan analyst James…
JPMorgan analyst James Gordon upgraded Lundbeck to Neutral from Underweight with a NOK 265 price target. The downgrade revision cycle has played out post the company's 2020 outlook, Gordon tells investors in a research note.
Lundbeck, Alder Biopharmaceuticals update information in tender offer materials » 08:1010/1110/11/19
H. Lundbeck (HLUYY) and…
H. Lundbeck (HLUYY) and Alder BioPharmaceuticals (ALDR) each filed updated tender offer materials with the U.S. Securities and Exchange Commission in connection with Lundbeck's pending tender offer, for all outstanding shares of Alder, whereby Alder stockholders are being offered an upfront payment for $18.00 per share in cash, along with one non-tradeable Contingent Value Right that entitles them to an additional $2.00 per share upon approval of eptinezumab by the European Medicines Agency, representing a total potential consideration $20.00 per share. The Offer commenced on 23 September 2019, and on the same day Lundbeck filed an offer to purchase and related letter of transmittal setting forth the terms of the Offer with the SEC and began mailing such materials to Alder stockholders. Also on 23 September 2019, Alder filed a solicitation and recommendation statement with the SEC under cover of Schedule 14D-9 recommending Alder stockholders tender their shares in the Offer and began mailing such statement to Alder stockholders. undbeck filed an amended Schedule TO that revises the offer to purchase to include, among other things, additional disclosure relating to the material terms of the CVR and the related CVR agreement. The amended Schedule TO does not constitute any change to the terms of the Offer, which is scheduled to expire at the end of the day, one minute after 11:59 P.M., Eastern Time, on October 21, 2019, unless the Offer is extended or terminated. Alder filed an amended Schedule 14D-9 that revises the solicitation and recommendation statement in respect of the Offer to include further detail regarding the share holdings of Alder's directors and executive officers. The amended Schedule 14D-9 does not constitute any change to the unanimous recommendation of the Alder Board that Alder's stockholders tender their shares in the Offer.